Simple Summary With a five-year survival rate of only 3% for the majority of patients,
pancreatic cancer is a global healthcare challenge. Radiomics and deep learning, two novel …

Currently, pancreatic adenocarcinoma mainly occurs after 60 years of age, and its prognosis
remains poor despite modest improvements in recent decades. The aging of the population …

Pancreatic ductal adenocarcinoma is characterized by a poor prognosis and a low median
survival, despite improvements observed for many other solid tumours. Intensive research …

Simple Summary Pancreatic cancer remains a major therapeutic challenge despite medical
advances. The incidence of pancreatic cancer is increasing, and this disease is associated …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers
with a median survival of 6 months after diagnosis. Intrinsic resistance to chemotherapeutics …

Introduction nab-Paclitaxel plus gemcitabine (nab-P+ G) and FOLFIRINOX (FFX) are among
the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas …

Although pancreatic cancer is only the twelfth most common type of cancer in the world, it
features a very unfavorable prognosis. The mortality rate almost equals the incidence rate …

Background The global burden of pancreatic cancer has steadily increased, while the
prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the …

Abstract Background FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have
been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC) …

Age‐related pathological changes in the pancreas have been unclear because they are
often minor and nonspecific. However, recent studies have shown that they are closely …